Shares of Intensity Therapeutics, Inc. (INTS) are up 142% on Friday after the company announced positive Phase 2 INVINCIBLE trial data of INT230-6 in patients with early-stage breast cancer without chemotherapy.
INTS is trading on the Nasdaq at $10.18, up 142.38% or $5.98 per share. It has traded between $2.01 and $11.09 in the past 52-week period.
The INVINCIBLE Trial was a randomized Phase 2 study that involved women with newly diagnosed, operable early-stage intermediate or high-grade T1-T2 invasive breast cancers.
The trial data revealed that INT230-6 has a favorable safety profile and is well-tolerated. Over 95% of the treatment-emergent adverse events (TEAEs) reported were low-grade 1 or 2 primarily localized pain, fatigue, and nausea.
It was also found that a single injection of INT230-6 could induce up to >95% necrosis of a tumor.
Angel Arnaout, M.D., MSc., who is a Professor of Surgery at the University of Ottawa and Co-Lead of the Ontario Institute for Cancer Research's Window-of-Opportunity Network, stated that the ability of INT230-6 to induce necrosis and immune effects before a patient's surgery, while maintaining a safe profile, would be a significant step forward for the treatment of breast cancer and potentially other cancers as well.
This data was presented during the 2023 San Antonio Breast Cancer Symposium (SABCS) in a Podium Poster Spotlight discussion session.
For comments and feedback: editorial@rttnews.com